TCGA (The Cancer Genome Atlas) data show that 4% of breast tumours have CCL5 dysregulation (2% in basal tumours), mainly related to genetic downregulation which has been previously associated with breast cancer progression.22CCL5 expressed by tumours recruits tumour infiltrant lymphocytes (TILs). This evidence concerns the gene CCL5 and breast cancer.